Related Experiment Videos
Gentamicin kinetics in the neonate
Insights
Gentamicin elimination half-life in neonates is linked to postconceptual age. Infants under 34 weeks may accumulate gentamicin, necessitating extended dosing intervals and close monitoring to prevent nephrotoxicity.
Area of Science:
- Neonatal Pharmacology
- Pediatric Nephrology
- Pharmacokinetics
Background:
- Gentamicin is a critical antibiotic for neonatal infections.
- Accurate dosing is essential due to narrow therapeutic windows and potential toxicity.
- Neonatal physiology significantly impacts drug elimination.
Purpose of the Study:
- To determine gentamicin elimination half-life in neonates.
- To investigate the relationship between postconceptual age and gentamicin pharmacokinetics.
- To assess the risk of gentamicin accumulation and nephrotoxicity in neonates.
Main Methods:
- Serum gentamicin levels were measured in neonates (25-42 weeks postconceptual age).
- Elimination half-life (t 1/2e) was calculated using a one-compartment open model.
- Intravenous gentamicin was administered at various dosage intervals (2.5 mg/Kg/dose).
Main Results:
- Gentamicin accumulation was observed in 82% of infants younger than 34 weeks.
- Elimination half-life was longest in infants younger than 30 weeks (8.8 ± 0.7 hours).
- Half-life decreased with increasing postconceptual age, being shortest in infants >34 weeks (6.2 ± 0.5 hours).
Conclusions:
- Gentamicin elimination is significantly influenced by postconceptual age in neonates.
- Current recommended dosing may lead to gentamicin accumulation and nephrotoxicity in premature infants.
- Lengthening the gentamicin dosage interval to 18 hours for infants <34 weeks, with plasma level monitoring, is recommended.
Abstract:
Gentamicin serum levels were measured and elimination half-life was calculated in a group of neonates with postconceptual ages ranging between 25-42 weeks. Infants were receiving intravenous gentamicin (2.5 mg/Kg/dose) at various dosage intervals and t 1/2e was calculated using a one-compartment open model. Evidence of gentamicin accumulation was present in 82% of infants 34 weeks. T 1/2e was 8.8 +/- .7 hours in infants 30 weeks, 7.8 +/- 1.1 hour in infants between 30-34 weeks and 6.2 +/- .5 in infants greater than 34 weeks. The results of the study suggest that gentamicin elimination is related to postconceptual age and that infants treated with recommended dosage regimens may have possible gentamicin tissue accumulation and nephrotoxicity. Therefore, the dosage interval may have to be lengthened to 18 hours in infants less than 34 weeks with close gentamicin plasma level monitoring.